200% in one day: success in trial sends pharmaceutical company's stock soaring

Shares of the American biotech company Kodiak surged approximately 200% on the Nasdaq after publishing positive Phase 3 trial results for two drugs treating retinal diseases. The company reported that both drugs met the trial's primary endpoint, potentially paving the way for a marketing authorization application. The surge adds to a rally of over 450% in the stock over the past 12 months.

Shares of the American biotech company Kodiak (ticker: KOD) are surging today on the Nasdaq by approximately 200%, after the company published positive results from a Phase 3 clinical trial for treating eye diseases. The company specializes in developing drugs for retinal diseases, including wet age-related macular degeneration. Both tested drugs met the trial's primary endpoint and showed results non-inferior to existing treatment. The results may allow Kodiak to advance toward submitting a marketing authorization application, and if approved, the drugs could compete in the existing market. The surge adds to a rally of over 450% in the stock over the past 12 months. Kodiak was once a biotech market star: in 2020, the stock soared on positive data from KSI-301 trials, raised over $600 million, and signed a manufacturing agreement with Lonza, but later enthusiasm faded and the stock erased most of its gains.